2007: RA New and Established Therapies: Efficacy and Safety II
Search or Browse by Day

RA New and Established Therapies: Efficacy and Safety II

940
Inhibition of Radiographic Progression by Lyophilized Certolizumab Pegol Added to Methotrexate in Comparison with Methotrexate Alone in Patients with Rheumatoid Arthritis: The RAPID 1 Trial
941
Efficacy and Rapid Response of Certolizumab Pegol Liquid Formulation in Combination with Methotrexate (MTX) in Patients with Active Rheumatoid Arthritis Despite MTX Therapy: Results from the RAPID 2 Study
942
The Efficacy of Abatacept in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNF Therapy: The ARRIVE Trial
943
Response to Influenza Vaccine in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-TNF Therapy Treated with Abatacept in the ARRIVE Trial
944
Denosumab-Mediated Increase of Hand Bone Mineral Density (BMD) in Patients with Rheumatoid Arthritis is Associated with Decreased Progression of Bone Erosion
945
Effectiveness and Safety of Adalimumab (HUMIRA®) After Failure of Etanercept or Infliximab Treatment in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
946
Certolizumab Pegol Results in Clinically Meaningful Improvements in Physical Function and Health-Related Quality of Life in Patients with Active Rheumatoid Arthritis Despite Treatment with Methotrexate
947
Preliminary Safety and Efficacy of LTβR-Ig (BG9924) in the Treatment of Rheumatoid Arthritis (RA)
948
New Modified-Release (MR) Prednisone Tablet Shows Sustained Reduction of Morning Stiffness and Interleukin-6 (IL-6) in Patients with Rheumatoid Arthritis (RA)
949
Comparing Ayurvedic (India) Herbal drugs and HCQS (hydroxychloroquin sulfate) in the Treatment of Rheumatoid Arthritis (RA): A Randomized, Double Blind, Multi-Centric Exploratory Drug Trial of 24 Weeks Duration
950
Maintained Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients Receiving Background Methotrexate through 5 Years of Treatment
951
A Clinical Study of Very Low Dose Prednisolone and Paroxetine for Active RA
952
Significantly Higher Disease Remission over 3 Years with Etanercept and Methotrexate Versus Either Therapy Alone: Longitudinal Analysis of the TEMPO Results
953
Denosumab Increases Bone Mineral Density in Patients with Glucocorticoid-Induced Bone Loss and Rheumatoid Arthritis
954
Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD056, A Novel P2X7 Receptor Antagonist, In Healthy Volunteers
955
Change in Bone Mineral Density in Rheumatoid Arthritis Patients after Adalimumab Therapy: A Beneficial Role for Prednisone Use?
956
Infliximab Dose Escalation in Rheumatoid Arthritis Patients in the START Trial: The Effect of Infliximab Pharmacokinetics and Immunogenicity
957
Efficacy and Safety of up to 10 Years of Etanercept (Enbrel®) Therapy in North American Patients With Early and Long-Standing Rheumatoid Arthritis
958
The Rate of Infection Adverse Events (AE's) is Increased as Disease Activity Increases in Rheumatoid Arthritis (RA)
959
Adalimumab Safety Profile in Global Clinical Trials and Reduction in Standardized Mortality Ratios (SMR) Across Multiple Indications
960
Clinical Trial Safety Data of Events of Interest in Patients Receiving Etanercept (ENBREL®) across Approved Indications
961
Impact of 3 TNFα Blockers on Markers of Autoimmunity in Rheumatoid Arthritis and Spondylarthropathy
962
Effect of Tumor Necrosis Factor alpha Blockade on Inflammatory and Haemostatic Biomarkers in Patients with Rheumatoid Arthritis
963
High Association of Anti-DNA Antibotides and Lowered Platelet Counts in Arthritic Patients Treated With Infliximab: A 1-Year Follow-Up Study
964
Effects of Folic Acid Supplementation on Both Efficacy and Safety During Low-Dose Methotrexate Treatment in Rheumatoid Arthritis
965
Co-morbidity Twelve Years after COBRA Combination Therapy in Patients with Early Rheumatoid Arthritis
966
Steroid Use among RA Patients Pre and Post TNF Inhibitor Therapy: Decreased Steroid Use with TNF Inhibitors but More Than a Third Of Patients Still Require High Maintenance Doses
967
Rituximab (rtx) Treatment of Active Rheumatoid Arthritis (ra) in Daily Practice in Germany: Interim Analysis of Effectiveness and Safety after 9 Months
968
The Feasibility and Acceptability of Withdrawal of Non-Steroidal Anti-Inflammatory Drugs from Patients with Stable Rheumatoid Arthritis
969
Duration of Use of Anti-TNF Therapy in Rheumatoid Arthritis
970
Comparison of Switching Patterns Among Anti-Tumor Necrosis Factors in the Treatment of Rheumatoid Arthritis
971
Comparison of Therapeutic Persistence Among Anti-Tumor Necrosis Factors in the Treatment of Rheumatoid Arthritis
972
Clinical Evolution after Discontinuation of Anti-TNF Treatment in RA Patients in Remission
973
Long-Term Effectiveness During Infliximab or Etanercept Therapy: A Systematic Review of Observational Studies
974
Route of Administration of Biologic Therapy: What do Patients Prefer?
975
Role of Hypoxia-Inducible Factor-1α in Hypoxia-Induced Expressions of IL-8, MMP-1 and -3 in Rheumatoid Fibroblast-Like Synoviocytes
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>